Crosstalk between Rac1- mediated actin regulation and ROS production
Author
dc.contributor.author
Acevedo, Alejandro
Author
dc.contributor.author
González Billault, Christian
Admission date
dc.date.accessioned
2018-07-26T20:42:59Z
Available date
dc.date.available
2018-07-26T20:42:59Z
Publication date
dc.date.issued
2018
Cita de ítem
dc.identifier.citation
Free Radical Biology and Medicine, 116 (2018): 101–113
es_ES
Identifier
dc.identifier.other
10.1016/j.freeradbiomed.2018.01.008
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/150351
Abstract
dc.description.abstract
The small RhoGTPase Rac1 is implicated in a variety of events related to actin cytoskeleton rearrangement. Remarkably, another event that is completely different from those related to actin regulation has the same relevance; the Rac1-mediated production of reactive oxygen species (ROS) through NADPH oxidases (NOX). Each outcome involves different Rac1 downstream effectors; on one hand, events related to the actin cytoskeleton require Rac1 to bind to WAVEs proteins and PAKs that ultimately promote actin branching and turnover, on the other, NOX-derived ROS production demands active Rac1 to be bound to a cytosolic activator of NOX. How Rac1-mediated signaling ends up promoting actin-related events, NOX-derived ROS, or both is poorly understood. Rac1 regulators, including scaffold proteins, are known to exert tight control over its functions. Hence, evidence of Rac1 regulatory events leading to both actin remodeling and NOX-mediated ROS generation are discussed. Moreover, cellular functions linked to physiological and pathological conditions that exhibit crosstalk between Rac1 outcomes are analyzed, while plausible roles in neuronal functions (and dysfunctions) are highlighted. Together, discussed evidence shed light on cellular mechanisms which requires Rac1 to direct either actin- and/or ROS-related events, helping to understand crucial roles of Rac1 dual functionality.
es_ES
Patrocinador
dc.description.sponsorship
CONICYT under the FONDAP
15150012
Fondecyt Program
1140325